Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells.

Lu H, Yang Y, Gad E, Wenner CA, Chang A, Larson ER, Dang Y, Martzen M, Standish LJ, Disis ML.

Clin Cancer Res. 2011 Jan 1;17(1):67-76. doi: 10.1158/1078-0432.CCR-10-1763. Epub 2010 Nov 10.

2.

TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy.

Lu H, Yang Y, Gad E, Inatsuka C, Wenner CA, Disis ML, Standish LJ.

Clin Cancer Res. 2011 Nov 1;17(21):6742-53. doi: 10.1158/1078-0432.CCR-11-1142. Epub 2011 Sep 14.

3.

Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant.

Engel AL, Sun GC, Gad E, Rastetter LR, Strobe K, Yang Y, Dang Y, Disis ML, Lu H.

Immunobiology. 2013 Dec;218(12):1468-76. doi: 10.1016/j.imbio.2013.05.001. Epub 2013 May 13.

4.

Polysaccharide-K (PSK) increases p21(WAF/Cip1) and promotes apoptosis in pancreatic cancer cells.

Rosendahl AH, Sun C, Wu D, Andersson R.

Pancreatology. 2012 Nov-Dec;12(6):467-74. doi: 10.1016/j.pan.2012.09.004. Epub 2012 Sep 23.

PMID:
23217280
5.

The TLR2 agonist in polysaccharide-K is a structurally distinct lipid which acts synergistically with the protein-bound β-glucan.

Quayle K, Coy C, Standish L, Lu H.

J Nat Med. 2015 Apr;69(2):198-208. doi: 10.1007/s11418-014-0879-z. Epub 2014 Dec 16.

PMID:
25510899
6.

Krestin (PSK).

Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K.

Cancer Treat Rev. 1984 Jun;11(2):131-55. Review.

PMID:
6238674
8.

Oral administration of PSK can improve the impaired anti-tumor CD4+ T-cell response in gut-associated lymphoid tissue (GALT) of specific-pathogen-free mice.

Harada M, Matsunaga K, Oguchi Y, Iijima H, Tamada K, Abe K, Takenoyama M, Ito O, Kimura G, Nomoto K.

Int J Cancer. 1997 Jan 27;70(3):362-72.

9.

Gamma delta T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK.

Inatsuka C, Yang Y, Gad E, Rastetter L, Disis ML, Lu H.

Cancer Immunol Immunother. 2013 Aug;62(8):1335-45. doi: 10.1007/s00262-013-1436-4. Epub 2013 May 18.

10.

Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented cytotoxic T lymphocytes.

Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Takahara A, Odahara S, Tsukinaga S, Yukawa T, Mitobe J, Matsudaira H, Nagatsuma K, Uchiyama K, Kajihara M, Arihiro S, Imazu H, Arakawa H, Kan S, Komita H, Ito M, Ohkusa T, Gong J, Tajiri H.

PLoS One. 2013;8(3):e59280. doi: 10.1371/journal.pone.0059280. Epub 2013 Mar 15.

11.
12.

TLR2, but not TLR4, is required for effective host defence against Chlamydia respiratory tract infection in early life.

Beckett EL, Phipps S, Starkey MR, Horvat JC, Beagley KW, Foster PS, Hansbro PM.

PLoS One. 2012;7(6):e39460. doi: 10.1371/journal.pone.0039460. Epub 2012 Jun 19.

13.

Activation of human natural killer cells by the protein-bound polysaccharide PSK independently of interferon and interleukin 2.

Kariya Y, Inoue N, Kihara T, Okamoto N, Sugie K, Mori T, Uchida A.

Immunol Lett. 1992 Feb 15;31(3):241-5.

PMID:
1372283
14.

PSK as a chemopreventive agent.

Kobayashi H, Matsunaga K, Fujii M.

Cancer Epidemiol Biomarkers Prev. 1993 May-Jun;2(3):271-6. Review.

15.

TLR2 engagement on dendritic cells promotes high frequency effector and memory CD4 T cell responses.

Chandran SS, Verhoeven D, Teijaro JR, Fenton MJ, Farber DL.

J Immunol. 2009 Dec 15;183(12):7832-41. doi: 10.4049/jimmunol.0901683.

16.
17.

Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates.

Zom GG, Khan S, Britten CM, Sommandas V, Camps MG, Loof NM, Budden CF, Meeuwenoord NJ, Filippov DV, van der Marel GA, Overkleeft HS, Melief CJ, Ossendorp F.

Cancer Immunol Res. 2014 Aug;2(8):756-64. doi: 10.1158/2326-6066.CIR-13-0223. Epub 2014 Apr 21.

20.

A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth.

Oldford SA, Haidl ID, Howatt MA, Leiva CA, Johnston B, Marshall JS.

J Immunol. 2010 Dec 1;185(11):7067-76. doi: 10.4049/jimmunol.1001137. Epub 2010 Nov 1.

Supplemental Content

Support Center